Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19
Open Access
- 22 February 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (4)
Abstract
The coronavirus disease 19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the worst public health crisis in a century. However, knowledge about the dynamics of antibody responses in patients with COVID-19 is still poorly understood. In this study, we performed a serological study with serum specimens collected at the acute and the convalescent phases from 104 patients with severe COVID-19 who were part of the first wave of COVID-19 cases in Wuhan, China. Our findings revealed that neutralizing antibodies to SARS-CoV-2 are persistent for at least 6 months in patients with severe COVID-19, despite that IgG levels against the receptor binding domain (RBD) and nucleocapsid protein (N) IgG declined from the acute to the convalescent phase. Moreover, we demonstrate that the level of RBD-IgG is capable of correlating with SARS-CoV-2–neutralizing activities in COVID-19 serum. In summary, our findings identify the magnitude, functionality, and longevity of antibody responses in patients with COVID-19, which sheds light on the humoral immune response to COVID-19 and would be beneficial for developing vaccines.Keywords
Funding Information
- National Science and Technology Major Project (2018ZX10733403, 2020ZX09201-001)
- National Natural Science Foundation of China (32000115, 81873964)
- Strategic Priority Research Program of CAS (XDB29010300)
- Grant from the CAS Youth Innovation Promotion Association (2020332)
This publication has 39 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19New England Journal of Medicine, 2020
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort studyThe Lancet Infectious Diseases, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoVNature Communications, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- The proximal origin of SARS-CoV-2Nature Medicine, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- U1 snRNP regulates cancer cell migration and invasion in vitroNature Communications, 2020
- Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing AntibodyJournal of Biological Chemistry, 2006